Report Sections

See All Reports

Coronavirus Infections (840) Severe Acute Respiratory Syndrome (575) Infection (491) Pneumonia (381) Communicable Diseases (217) Respiratory Distress Syndrome, Adult (187) Acute Lung Injury (148) Respiratory Distress Syndrome, Newborn (148) (134) Syndrome (129) Virus Diseases (98) Depression (92) Pneumonia, Viral (81) Critical Illness (69) Anxiety Disorders (57) Neoplasms (47) Respiratory Tract Infections (46) Disease (41) Diabetes Mellitus (39) Cardiovascular Diseases (38) Stress Disorders, Post-Traumatic (38) Emergencies (36) Wounds and Injuries (36) Depressive Disorder (35) Inflammation (35) Lung Diseases (33) Stress Disorders, Traumatic (33) Stress, Psychological (33) Respiratory Tract Diseases (31) Hypoxia (30) Lung Injury (30) Acute Kidney Injury (29) Mental Disorders (29) Thrombosis (29) Influenza, Human (27) Hypertension (25) Respiration Disorders (23) Disease Progression (22) Fibrosis (22) Cognitive Dysfunction (21) Olfaction Disorders (21) Arthritis (20) Diabetes Mellitus, Type 2 (20) Sclerosis (20) Burnout, Psychological (19) Multiple Sclerosis (19) Pulmonary Disease, Chronic Obstructive (19) Respiratory Aspiration (19) Thromboembolism (19) Embolism (18) Lung Diseases, Obstructive (18) Pulmonary Fibrosis (18) HIV Infections (17) Kidney Diseases (17) Stroke (17) Blood Coagulation Disorders (16) Heart Failure (16) Hemostatic Disorders (16) Pulmonary Embolism (16) Arthritis, Rheumatoid (15) Asthma (15) Chronic Disease (15) Heart Diseases (15) Lung Diseases, Interstitial (15) Lung Neoplasms (15) Myocardial Infarction (15) Substance-Related Disorders (15) Autism Spectrum Disorder (14) Chronic Pain (14) Crohn Disease (14) Brain Injuries (13) Diabetes Mellitus, Type 1 (13) Infarction (13) Venous Thrombosis (12) Autistic Disorder (11) Carcinoma (11) Colitis (11) Colitis, Ulcerative (11) Dyspnea (11) Feeding and Eating Disorders (11) Obesity (11) Rheumatic Diseases (11) Ulcer (11) Alzheimer Disease (10) Burnout, Professional (10) Leukemia (10) Lymphoma (10) Myocarditis (10) Overweight (10) Parkinson Disease (10) Pregnancy Complications (10) Renal Insufficiency, Chronic (10) Respiratory Syncytial Virus Infections (10) Sepsis (10) Brain Injuries, Traumatic (9) Collagen Diseases (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Dementia (9) Depression, Postpartum (9) Frailty (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Musculoskeletal Pain (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Weight Loss (9) Alcohol Drinking (8) Alcoholism (8) Hematologic Neoplasms (8) Infertility (8) Ischemia (8) Parasomnias (8) Problem Behavior (8) Psychotic Disorders (8) RNA Virus Infections (8) Breast Neoplasms (7) Convalescence (7) Coronary Disease (7) Dyssomnias (7) Fatigue (7) Metabolic Syndrome (7) Migraine Disorders (7) Myocardial Ischemia (7) Neoplasm Metastasis (7) Psoriasis (7) Schizophrenia (7) Shock (7) Spinal Cord Injuries (7) Toxemia (7) Acute Coronary Syndrome (6) Brain Diseases (6) Bronchiectasis (6) Carcinoma, Non-Small-Cell Lung (6) Child Development Disorders, Pervasive (6) Colorectal Neoplasms (6) Deglutition Disorders (6) Delirium (6) Disease Susceptibility (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Kidney Failure, Chronic (6) Lupus Erythematosus, Systemic (6) Lymphopenia (6) Multiple Organ Failure (6) Neurologic Manifestations (6) Osteoarthritis (6) (6) Pediatric Obesity (6) Prostatic Neoplasms (6) Sleep Apnea Syndromes (6) Sleep Apnea, Obstructive (6) Appendicitis (5) Arthritis, Psoriatic (5) Autoimmune Diseases (5) Coronaviridae Infections (5) Cross Infection (5) Depressive Disorder, Major (5) Dermatitis (5) Disseminated Intravascular Coagulation (5) Fibromyalgia (5) Gastroparesis (5) Head and Neck Neoplasms (5) Hypersensitivity (5) Idiopathic Pulmonary Fibrosis (5) Leukemia, Lymphoid (5) Metabolic Diseases (5) Mobility Limitation (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) Pancreatic Neoplasms (5) Premature Birth (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Acute Disease (4) Adenoviridae Infections (4) Amyotrophic Lateral Sclerosis (4) Anemia, Sickle Cell (4) Arrhythmias, Cardiac (4) Asymptomatic Diseases (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Carcinoma, Renal Cell (4) Cognition Disorders (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Dermatitis, Atopic (4) Digestive System Diseases (4) Eczema (4) Embolism and Thrombosis (4) Endometriosis (4) Gastrointestinal Diseases (4) Headache (4) Heart Arrest (4) Hematologic Diseases (4) Hemophilia A (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Macular Degeneration (4) Malnutrition (4) Motor Neuron Disease (4) (4) Mycobacterium Infections (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Spondylarthritis (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Apnea (3) Bacteremia (3) Bacterial Infections (3) Bulimia (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Congenital Abnormalities (3) Developmental Disabilities (3) Dysgeusia (3) Endocrine System Diseases (3) Eye Diseases (3) Fatigue Syndrome, Chronic (3) Fatty Liver (3) Fever (3) Fistula (3) Fractures, Bone (3) Ganglion Cysts (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Heart Defects, Congenital (3) Hepatitis C (3) Huntington Disease (3) Hyperglycemia (3) Hypothermia (3) Kidney Calculi (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Leukemia, Myeloid, Acute (3) Macular Edema (3) Measles (3) Melanoma (3) Meningitis (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Myeloma (3) Multiple Sclerosis, Relapsing-Remitting (3) Myelodysplastic Syndromes (3) Myeloproliferative Disorders (3) Neoplasms, Plasma Cell (3) Neuroendocrine Tumors (3) Non-alcoholic Fatty Liver Disease (3) Obesity, Morbid (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Nervous System Diseases (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Shock, Septic (3) Sleep Wake Disorders (3) Small Cell Lung Carcinoma (3) Suicidal Ideation (3) Tachycardia (3) Taste Disorders (3) Tuberculosis (3) Ageusia (2) Agoraphobia (2) Alcoholic Intoxication (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Aortic Valve Stenosis (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrophy (2) Back Pain (2) Behcet Syndrome (2) Binge-Eating Disorder (2) Bipolar Disorder (2) Bronchitis (2) Bronchitis, Chronic (2) Bronchopulmonary Dysplasia (2) Caliciviridae Infections (2) Carcinoma, Small Cell (2) Carcinoma, Squamous Cell (2) Cataract (2) Cholangitis (2) Clinical Deterioration (2) Clostridium Infections (2) Communicable Diseases, Emerging (2) Communication Disorders (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Conjunctivitis (2) Depressive Disorder, Treatment-Resistant (2) Diabetic Nephropathies (2) Diabetic Neuropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Epilepsy (2) Facies (2) Fractures, Stress (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Genetic Predisposition to Disease (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hepatitis (2) Hepatitis A (2) Humeral Fractures (2) Hyperkinesis (2) Hyperphagia (2) Hyperplasia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Infertility, Male (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid (2) Low Back Pain (2) Lymphedema (2) Lymphoma, B-Cell (2) Lymphoma, Mantle-Cell (2) Lymphoproliferative Disorders (2) Meningitis, Meningococcal (2) Mood Disorders (2) Mucositis (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Nephrolithiasis (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Oropharyngeal Neoplasms (2) Pain (2) Pain, Postoperative (2) Pancreatitis (2) Paresis (2) Periodontal Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Bacterial (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Preleukemia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Spinal Diseases (2) Sprains and Strains (2) Squamous Cell Carcinoma of Head and Neck (2) Stillbirth (2) Stomatitis (2) Suicide (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Thyroid Diseases (2) Trauma and Stressor Related Disorders (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Wet Macular Degeneration (2) Yellow Fever (2) Abortion, Spontaneous (1) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Aggression (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia (1) Anemia, Aplastic (1) Anemia, Iron-Deficiency (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Ankle Fractures (1) Anorexia (1) Anorexia Nervosa (1) Arachnoiditis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Brain Neoplasms (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Brucellosis (1) Bruxism (1) Bulimia Nervosa (1) (1) Calculi (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Carcinoma, Ovarian Epithelial (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colitis, Ulcerativ (1) Colonic Diseases (1) (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Coronavirus Infect (1) Cough (1) Coxsackievirus Infections (1) Crohn Dise (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) DiGeorge Syndrome (1) Diabetic Foot (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dry Eye Syndromes (1) Dysentery, Bacillary (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epstein-Barr Virus Infections (1) Escherichia coli Infections (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gambling (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Geographic Atrophy (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Glomerulonephritis, Membranous (1) Guillain-Barre Syndrome (1) Halitosis (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hot Flashes (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperkalemia (1) Hyperphosphatemia (1) Hypersensitivity, Immediate (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infectious Mononucleosis (1) Infertility, Female (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratoconjunctivitis Sicca (1) Keratosis (1) Keratosis, Actinic (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Leukemia, Prolymphocytic (1) Leukemia, Prolymphocytic, T-Cell (1) Lichen Sclerosus et Atrophicus (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Lung Ne (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Meningomyelocele (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myelodysplastic-Myeloproliferative Diseases (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplasms, Germ Cell and Embryonal (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Oligospermia (1) Opioid-Related Disorders (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Parkin (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Pocket (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Polyps (1) Pregnancy in Diabetics (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Heart Disease (1) Rabies (1) Radiculopathy (1) Rectal Fistula (1) Rectal Neoplasms (1) Reperfusion Injury (1) Resp (1) Respiratory Distre (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Restless Legs Syndrome (1) Retinal Vein Occlusion (1) Rhinitis (1) Rhinitis, Allergic (1) Rhinitis, Allergic, Seasonal (1) Sarcoma (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Shoulder Fractures (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Speech Sound Disorder (1) Spina Bifida Cystica (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylitis (1) Spondylitis, Ankylosing (1) Spondylolisthesis (1) Status Epilepticus (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Synovial Cyst (1) Tachycardia, Sinus (1) Tachycardia, Supraventricular (1) Tachycardia, Ventricular (1) Tachypnea (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tissue Adhesions (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Meningeal (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Lichen Sclerosus (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D011658: Pulmonary Fibrosis

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (31)


Name (Synonyms) Correlation
drug1223 D-dimer,CBC.ESR,CRP, Wiki 0.24
drug1637 Facial mask Wiki 0.24
drug1054 Collagen-Polyvinylpyrrolidone Wiki 0.24
Name (Synonyms) Correlation
drug1724 Fuzheng Huayu Tablet Wiki 0.24
drug2037 IN01 vaccine Wiki 0.24
drug4867 bovhyaluronidase azoxymer Wiki 0.24
drug2802 Nintedanib 150 MG Wiki 0.24
drug494 BI 1015550 Wiki 0.24
drug1613 FFP2 Wiki 0.24
drug4804 [18F]FP-R01-MG-F2 Wiki 0.24
drug941 Centricyte 1000 Wiki 0.24
drug2801 Nintedanib Wiki 0.24
drug2460 MFS Wiki 0.24
drug2906 ORIN1001 Wiki 0.24
drug2357 Liver function tests ,serum ferritin and PCR for COVID-19 . Wiki 0.24
drug2050 IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki 0.24
drug2333 Liberase Enzyme (Roche) Wiki 0.24
drug2072 Imaging Wiki 0.24
drug2803 Nintedanib 150 MG [Ofev] Wiki 0.24
drug4156 Sterile Normal Saline for Intravenous Use Wiki 0.24
drug4901 control Wiki 0.24
drug2611 Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki 0.24
drug3452 Pulmonary function tests Wiki 0.24
drug512 BIO 300 Oral Suspension Wiki 0.24
drug44 20 Mg Prednisone for 14 days Wiki 0.24
drug4259 TD-1058 Wiki 0.24
drug5187 respiratory function rehabilitation training Wiki 0.24
drug4691 Vitamin C tablets Wiki 0.24
drug3193 Pirfenidone Wiki 0.17
drug3195 Placebo Wiki 0.09
drug663 Blood sampling Wiki 0.08

Correlated MeSH Terms (15)


Name (Synonyms) Correlation
D005355 Fibrosis NIH 0.55
D054990 Idiopathic Pulmonary Fibrosis NIH 0.53
D017563 Lung Diseases, Interstitial NIH 0.24
Name (Synonyms) Correlation
D011649 Pulmonary Alveolar Proteinosis NIH 0.24
D015209 Cholangitis, Sclerosing NIH 0.24
D002761 Cholangitis NIH 0.17
D008171 Lung Diseases, NIH 0.16
D012120 Respiration Disorders NIH 0.05
D012140 Respiratory Tract Diseases NIH 0.04
D011024 Pneumonia, Viral NIH 0.03
D003141 Communicable Diseases NIH 0.02
D011014 Pneumonia NIH 0.01
D007239 Infection NIH 0.01
D045169 Severe Acute Respiratory Syndrome NIH 0.01
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (6)


Name (Synonyms) Correlation
HP:0002206 Pulmonary fibrosis HPO 1.00
HP:0006515 Interstitial pneumonitis HPO 0.24
HP:0006517 Intraalveolar phospholipid accumulation HPO 0.24
Name (Synonyms) Correlation
HP:0030151 Cholangitis HPO 0.17
HP:0002088 Abnormal lung morphology HPO 0.16
HP:0002090 Pneumonia HPO 0.01

Clinical Trials

Navigate: Correlations   HPO

There are 18 clinical trials


1 Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 With [18F]FP-R01-MG-F2 With PET/CT

Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT

NCT03183570
Conditions
  1. Idiopathic Pulmonary Fibrosis
  2. Primary Sclerosing Cholangitis
  3. Covid19 Pneumonia
Interventions
  1. Drug: [18F]FP-R01-MG-F2
MeSH:Cholangitis Cholangitis, Sclerosing Pneumonia Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Fibrosis
HPO:Cholangitis Pneumonia Pulmonary fibrosis

Primary Outcomes

Description: The SUVmax in a lung or liver with known IPF, COVID19 pneumonia, or PSC respectively will be compared to the SUVmax in a known healthy lung/liver. It is expected that the SUV max, which is a measurement of the maximum value of radiopharmaceutical uptake within the region of interest (ROI) in IPF, COVID19 pneumonia, and PSC will be higher than the SUV max in the healthy lung/liver.

Measure: SUV max comparison : IPF versus Healthy Lung, PSC versus Healthy Liver, COVID19 versus Healthy Lung

Time: an estimated average of 2 hours

Secondary Outcomes

Description: Blood samples for blood time-activity measurements taken at 1, 3, 5, 10, 30, and 60 minutes after tracer injection for tracer kinetic analysis. Tracer kinetic analysis shows radiopharmaceutical distribution from the blood to the tissues over time.

Measure: Time Activity Measurements

Time: an estimated average of 1 hours

Description: EKG data, vital signs and laboratory data collected before IV injection of [18F]FP-R01-MG-F2 and after completion of the scan will allow the investigators to evaluate the safety and tolerability of the radiopharmaceutical. This will be measured as the number of patients who successfully completed the study.

Measure: Incidence of Study Completion (Safety and Tolerability)

Time: an estimated average of 2 hours
2 The Efficacy of Treating Pulmonary Fibrosis and Pulmonary Function Injury in COVID-19 With the Fuzheng Huayu Tablets: a Multicenter Randomized Controlled Trial

According to previous studies, viral pneumonia can develop into pulmonary fibrosis, which can affect patients'lung function and even life health.This study aims to observe the efficacy and safety of Fuzheng Huayu Tablets in the treatment of pulmonary fibrosis after COVID-19.

NCT04279197
Conditions
  1. Pulmonary Fibrosis Due to COVID-19
Interventions
  1. Drug: Fuzheng Huayu Tablet
  2. Drug: Vitamin C tablets
  3. Other: Placebo
  4. Other: respiratory function rehabilitation training
MeSH:Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Evaluation of pulmonary fibrosis Improvement. pulmonary fibrosis judged by HRCT score.HRCT images are divided into four grades according to the score, and a reduction of one grade is an improvement.

Measure: The improvement proportion of pulmonary fibrosis

Time: Week 24

Secondary Outcomes

Description: Evaluation of Lung Function Improvement

Measure: Blood oxygen saturation

Time: Week 24

Description: Discomfort symptoms include dyspnea, cough, exhausted, fatigue, insomnia, sweating, poor appetite, diarrhea, etc., which are common manifestations of patients with COVID-19

Measure: Clinical symptom score

Time: Week 24

Description: This scale can reflect the quality of life of patients to some extent.

Measure: Quality of Life-BREF (QOL-BREF)

Time: Week 24

Description: This scale can reflect the quality of life of patients to some extent.

Measure: Patient Health Questionnaire-9(PHQ-9)

Time: Week 24

Description: This scale can reflect the quality of life of patients to some extent.

Measure: Generalized anxiety disorder-7(GAD-7)

Time: Week 24

Description: Evaluation of Lung Function Improvement

Measure: The 6-minute walk distance

Time: Week 24
3 Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection

COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality. A short review includes: - Early December, 2019 - A pneumonia of unknown cause was detected in Wuhan, China, and was reported to the World Health Organization (WHO) Country Office. - January 30th, 2020 - The outbreak was declared a Public Health Emergency of International Concern. - February 7th, 2020 - 34-year-old Ophthalmologist who first identified a SARS-like coronavirus) dies from the same virus. - February 11th, 2020 - WHO announces a name for the new coronavirus disease: COVID-19. - February 19th, 2020 - The U.S. has its first outbreak in a Seattle nursing home which were complicated with loss of lives.. - March 11th, 2020 - WHO declares the virus a pandemic and in less than three months, from the time when this virus was first detected, the virus has spread across the entire planet with cases identified in every country including Greenland. - March 21st, 2020 - Emerging Infectious Disease estimates the risk for death in Wuhan reached values as high as 12% in the epicenter of the epidemic and ≈1% in other, more mildly affected areas. The elevated death risk estimates are probably associated with a breakdown of the healthcare system, indicating that enhanced public health interventions, including social distancing and movement restrictions, should be implemented to bring the COVID-19 epidemic under control." March 21st 2020 -Much of the United States is currently under some form of self- or mandatory quarantine as testing abilities ramp up.. March 24th, 2020 - Hot spots are evolving and identified, particularly in the areas of New York-New Jersey, Washington, and California. Immediate attention is turned to testing, diagnosis, epidemiological containment, clinical trials for drug testing started, and work on a long-term vaccine started. The recovering patients are presenting with mild to severe lung impairment as a result of the viral attack on the alveolar and lung tissues. Clinically significant impairment of pulmonary function appears to be a permanent finding as a direct result of the interstitial lung damage and inflammatory changes that accompanied. This Phase 0, first-in-kind for humans, is use of autologous, cellular stromal vascular fraction (cSVF) deployed intravenously to examine the anti-inflammatory and structural potential to improve the residual, permanent damaged alveolar tissues of the lungs.

NCT04326036
Conditions
  1. Pulmonary Alveolar Proteinosis
  2. COPD
  3. Idiopathic Pulmonary Fibrosis
  4. Viral Pneumonia
  5. Coronavirus Infection
  6. Interstitial Lung Disease
Interventions
  1. Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)
  2. Device: Centricyte 1000
  3. Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution
  4. Drug: Liberase Enzyme (Roche)
  5. Drug: Sterile Normal Saline for Intravenous Use
MeSH:Infection Communicable Diseases Coron Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Lung Diseases Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Lung Diseases, Interstitial Pulmonary Alveolar Proteinosis
HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Intraalveolar phospholipid accumulation Pulmonary fibrosis

Primary Outcomes

Description: Reporting of Adverse Events or Severe Adverse Events Assessed by CTCAE v4.0

Measure: Incidence of Treatment-Emergent Adverse Events

Time: 1 month

Secondary Outcomes

Description: High Resolution Computerized Tomography of Lung (HRCT Lung) for Fluidda Analysis comparative at baseline and 3 and 6 months post-treatment comparative analytics

Measure: Pulmonary Function Analysis

Time: baseline, 3 Month, 6 months

Description: Finger Pulse Oximetry taken before and after 6 minute walk on level ground, compare desaturation tendency

Measure: Digital Oximetry

Time: 3 months, 6 months
4 Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study

This center intends to conduct a single-center, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.

NCT04338802
Conditions
  1. COVID-19
  2. Nintedanib
  3. Safety
  4. Effect of Drugs
Interventions
  1. Drug: Nintedanib 150 MG
  2. Other: Placebo
MeSH:Pulmonary Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Changes in forced vital capacity (FVC) after treatment compared to baseline.

Measure: Changes in forced vital capacity (FVC)

Time: 8 weeks

Secondary Outcomes

Description: Changes incarbon monoxide dispersion (DLco%) after treatment compared to baseline.

Measure: Changes in carbon monoxide dispersion (DLco%)

Time: 8 weeks

Description: Changes in the six-minute walk test (6MWT) after treatment compared to baseline.

Measure: Changes in the six-minute walk test (6MWT)

Time: 8 weeks

Description: Changes in High resolution CT score after treatment compared to baseline.The minimum and maximum values are 0 and 25 , and higher scores mean a worse outcome. As for the score, it is the expected value and will be determined according to the actual result

Measure: Changes in High resolution CT score

Time: 8 weeks
5 STUDY OF THE APPEARANCE OF LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION

Prospective, observational, multicenter study that will evaluate the changes in lung function that patients admitted with SARS-CoV-2 pneumonia will present according to the level of severity at 4, 12, 26 and 52 weeks after hospital discharge.

NCT04409275
Conditions
  1. Pulmonary Fibrosis
MeSH:Pulmonary Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: To analyze the number of patients who will develop pulmonary fibrotic changes, in the short and medium term, after surviving a bilateral pulmonary infection by SARS-CoV-2

Measure: Pulmonary fibrotic changes, short and medium term

Time: 12 months

Description: To study the degree of lung function impairment, specifically the restrictive changes in functional capacity and diffusion alterations and its relationship with clinical variables.

Measure: Degree of lung function impairment

Time: 6 and 12 months

Description: Examine the biological markers in the patients who will present this dysregulation of the curative response that will give rise to pulmonary fibrosing phenomena.

Measure: Biological markers

Time: 1 month
6 Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection

COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge. The virus originated in December 2019 in Wuhan, China, and has spread rapidly around the world. Currently, European countries, including Austria, are severely affected.The most common computed tomographic changes in acute lung injury include bilateral and subpleural milk glass opacity, consolidation in lower lobes, or both. In the intermediate phase of the infection (4-14 days after the onset of symptoms) a so-called "crazy paving" may occur. The most prominent radiological changes occur around day 10, followed by gradual resolution, which begins two weeks after the onset of symptoms. Given the phylogenetic relationship between SARS-CoV-1 and SARS-CoV-2, the similar clinical course in severe cases and overlapping CT patterns in the acute setting, persistent radiological and pulmonary functional changes in survivors are conceivable. It is also conceivable that a proportion of survivors will develop progressive ILD, either due to viral or ventilator-induced alveolar damage, or both. Here, the investigators intend to investigate COVID-19 survivors through clinical examinations, functional lung examinations, HR-CT scans, and by determining the "immunofibrotic" pattern in peripheral mononuclear cells (PBMCs) 1, 3, and 6 months after discharge.

NCT04416100
Conditions
  1. Covid-19
  2. Pulmonary Fibrosis
Interventions
  1. Diagnostic Test: Pulmonary function tests
  2. Diagnostic Test: Imaging
  3. Biological: Blood sampling
MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial
HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

Primary Outcomes

Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 1 month after discharge or diagnosis of COVID-19 disease by the use of HR-CT.

Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 1 month

Time: 1 month

Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 3 months after discharge or diagnosis of COVID-19 disease by the use of HR-CT

Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 3 months

Time: 3 months

Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 6 months after discharge or diagnosis of COVID-19 disease by the use of HR-CT

Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 6 months

Time: 6 months
7 A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally

To investigate the efficacy of BI 1015550 compared to placebo based on the change from baseline in Forced Vital Capacity (FVC). To investigate safety and tolerability of BI 1015550 in the overall trial population.

NCT04419506
Conditions
  1. Idiopathic Pulmonary Fibrosis
Interventions
  1. Drug: BI 1015550
  2. Drug: Placebo
MeSH:Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Measure: change from baseline in Forced Vital Capacity (FVC)

Time: up to 12 weeks

Secondary Outcomes

Measure: percentage of patients with Treatment Emergent Adverse Events (TEAE)

Time: up to 13 weeks
8 A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients

Randomized, double-blinded, placebo-controlled, two-arm study to evaluate the effectiveness and safety of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in 2019 Coronavirus Disease (COVID-19) patients recently discharged from the hospital. Patients will be randomized 1:1 to receive BIO 300 or placebo. All patients will receive the same background current standard of care.

NCT04482595
Conditions
  1. Pulmonary Fibrosis
Interventions
  1. Drug: BIO 300 Oral Suspension
  2. Drug: Placebo
MeSH:Pulmonary Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Diffusing capacity of the lungs for carbon monoxide (DLCO)

Measure: Change in DLCO

Time: 12 Weeks

Description: 6 minute walk test (6MWT)

Measure: Change in 6 Minute Walk Test

Time: 12 Weeks

Secondary Outcomes

Description: Forced vital capacity (FVC)

Measure: Change in FVC

Time: 12 Weeks, 6 Months and 12 Months

Description: Patient reported outcome to measure impact on overall health, daily life, and perceived well-being in patients with impaired pulmonary function. Scores range from 0-100 with higher scores indicating more limitations.

Measure: Change in St. George's Respiratory Questionnaire (SGRQ) Scores

Time: 12 Weeks, 6 Months and 12 Months

Description: Evidence of pulmonary fibrosis on high resolution computerized tomography (HRCT) scans of the lungs based on a 4-point Likert scale, where 0 is no evidence of fibrosis and 3 is severe fibrosis

Measure: Change in Pulmonary Fibrosis on HRCT Scan

Time: 12 Weeks, 6 Months and 12 Months

Description: Incidence of hospitalization after initial discharge and initiating treatment

Measure: Incidence of Re-Hospitalization

Time: 12 Months

Description: Mortality at 12 months after initiating treatment

Measure: All-Cause Mortality

Time: 12 Months

Description: Forced expiratory volume in one second (FEV1)

Measure: Change in FEV1

Time: 12 Weeks, 6 Months and 12 Months

Description: Ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC)

Measure: Change in FEV1/FVC Ratio

Time: 12 Weeks, 6 Months and 12 Months

Description: 6 minute walk test (6MWT)

Measure: Change in 6 Minute Walk Test

Time: 6 Months and 12 Months

Description: Oxygen saturation (pulse oximetry) at rest and during the 6 minute walk test (6MWT)

Measure: Change in Pulse Oximetry at Rest and During the 6MWT

Time: 12 Weeks, 6 Months and 12 Months

Description: Diffusing capacity of the lungs for carbon monoxide (DLCO)

Measure: Change in DLCO

Time: 6 Months and 12 Months

Description: Evaluate the safety of BIO 300 Oral Suspension treatment

Measure: Adverse Events Related to BIO 300 Oral Suspension

Time: 12 Months

Description: Monitoring of blood serum levels for bilirubin, C-reactive protein (CRP), creatinine, blood urea nitrogen (BUN), cholesterol and triglycerides (all reported as mg/dL)

Measure: Change in Clinical Laboratory Values

Time: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

Description: Monitoring of blood serum levels for troponin T, d-dimer and ferritin (all reported as ng/mL)

Measure: Change in Clinical Laboratory Values

Time: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

Description: Monitoring of blood serum levels for albumin (g/dL)

Measure: Change in Clinical Laboratory Values for Albumin

Time: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

Description: Monitoring of blood serum levels for alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) (all reported as Units/L)

Measure: Change in Clinical Laboratory Values for Serum Enzymes

Time: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

Description: Monitoring of white blood cell, red blood cell and platelet counts

Measure: Change in Complete Blood Counts with Differential

Time: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months

Other Outcomes

Description: Prescribed supplemental oxygen flow rate at night, rest and exertion

Measure: Change in Supplemental Oxygen Use

Time: 12 Weeks, 6 Months and 12 Months

Description: Duration of supplemental oxygen use

Measure: Change in Duration of Supplemental Oxygen Use

Time: 12 Weeks, 6 Months and 12 Months

Description: Expression levels of serum-derived cytokines (IL-1b, IL-6, IL-8, TNFa, and TGFb1)

Measure: Change in Serum Cytokine Expression

Time: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months
9 Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands

To date, little is known about the short and long-term complications of COVID-19. In order to obtain more insights in disease course and recovery of COVID-19 and to improve care after hospital admission, patients with COVID-19 will be monitored at home using an online home monitoring program for a period of 1 year.

NCT04488562
Conditions
  1. COVID-19
  2. Pulmonary Fibrosis
MeSH:Pulmonary Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Visual Analogue Scale: scores on fatigue, dyspnea, cough and general wellbeing on a scale ranging from 0-10. Higher score indicates more complaint.

Measure: VAS

Time: 3 months

Description: Visual Analogue Scale: scores on fatigue, dyspnea, cough and general wellbeing on a scale ranging from 0-10. Higher score indicates more complaint.

Measure: VAS

Time: 6 months

Description: Visual Analogue Scale: scores on fatigue, dyspnea, cough and general wellbeing on a scale ranging from 0-10. Higher score indicates more complaint.

Measure: VAS

Time: 12 months

Description: Body temperature measured with an thermometer

Measure: Temperature

Time: 3 months

Description: Oxygen saturation measured with an pulse oximeter

Measure: Oxygen measurements

Time: 3 months

Description: Oxygen saturation measured with an pulse oximeter

Measure: Oxygen measurements

Time: 6 months

Description: Oxygen saturation measured with an pulse oximeter

Measure: Oxygen measurements

Time: 12 months

Description: FVC change measured with home spirometry at 3 months (in %)

Measure: Forced Vital Capacity (FVC) home spirometry in %

Time: 3 months

Description: FVC change measured with home spirometry at 3 months (in L)

Measure: Forced Vital Capacity (FVC) home spirometry in L

Time: 3 months

Description: FVC change measured with home spirometry at 6 months (in %)

Measure: Forced Vital Capacity (FVC) home spirometry in %

Time: 6 months

Description: FVC change measured with home spirometry at 6 months (in L)

Measure: Forced Vital Capacity (FVC) home spirometry in L

Time: 6 months

Description: FVC change measured with home spirometry at 12 months (in L)

Measure: Forced Vital Capacity (FVC) home spirometry in L

Time: 12 months

Description: FVC change measured with home spirometry at 12 months (in %)

Measure: Forced Vital Capacity (FVC) home spirometry in %

Time: 12 months

Description: FVC change measured with hospital spirometry and saturation at 3 months (in %)

Measure: Forced Vital Capacity (FVC) hospital spirometry in %

Time: 3 months

Description: FVC change measured with hospital spirometry and saturation at 3 months (in L)

Measure: Forced Vital Capacity (FVC) hospital spirometry in L

Time: 3 months

Description: FVC change measured with hospital spirometry and saturation at 6 months (in %)

Measure: Forced Vital Capacity (FVC) hospital spirometry in %

Time: 6 months

Description: FVC change measured with hospital spirometry and saturation at 6 months (in L)

Measure: Forced Vital Capacity (FVC) hospital spirometry in L

Time: 6 months

Description: FVC change measured with hospital spirometry and saturation at 12 months (in %)

Measure: Forced Vital Capacity (FVC) hospital spirometry in %

Time: 12 months

Description: FVC change measured with hospital spirometry and saturation at 12 months (in L)

Measure: Forced Vital Capacity (FVC) hospital spirometry in L

Time: 12 months

Description: The percentage of patients completed weekly home spirometry

Measure: Adherence to weekly home spirometry

Time: 1 year after inclusion

Description: The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status

Measure: EQ5D

Time: Baseline

Description: The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status

Measure: EQ5D

Time: 6 weeks

Description: The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status

Measure: EQ5D

Time: 3 months

Description: The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status

Measure: EQ5D

Time: 6 months

Description: The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status

Measure: EQ5D

Time: 9 months

Description: The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status

Measure: EQ5D

Time: 12 months

Description: Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of ≥ 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.

Measure: FAS

Time: Baseline

Description: Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of ≥ 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.

Measure: FAS

Time: 6 weeks

Description: Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of ≥ 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.

Measure: FAS

Time: 3 months weeks

Description: Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of ≥ 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.

Measure: FAS

Time: 6 months weeks

Description: Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of ≥ 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.

Measure: FAS

Time: 9 months weeks

Description: Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of ≥ 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.

Measure: FAS

Time: 12 months weeks

Description: Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.

Measure: GRoC

Time: Baseline

Description: Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.

Measure: GRoC

Time: 6 weeks

Description: Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.

Measure: GRoC

Time: 3 months

Description: Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.

Measure: GRoC

Time: 6 months

Description: Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.

Measure: GRoC

Time: 9 months

Description: Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.

Measure: GRoC

Time: 12 months

Description: Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.

Measure: ABC tool

Time: Baseline

Description: Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.

Measure: ABC tool

Time: 6 weeks

Description: Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.

Measure: ABC tool

Time: 3 months

Description: Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.

Measure: ABC tool

Time: 6 months

Description: Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.

Measure: ABC tool

Time: 9 months

Description: Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.

Measure: ABC tool

Time: 12 months

Secondary Outcomes

Description: Correlation between FVC, HRCT patterns, symptoms and quality of life

Measure: Correlation between FVC, HRCT patterns, symptoms and quality of life

Time: 3 months

Description: Correlation between FVC, HRCT patterns, symptoms and quality of life

Measure: Correlation between FVC, HRCT patterns, symptoms and quality of life

Time: 6 months

Description: Correlation between FVC, HRCT patterns, symptoms and quality of life

Measure: Correlation between FVC, HRCT patterns, symptoms and quality of life

Time: 12 months

Description: Predictors for the course of recovery of COVID-19 infection after hospital admission

Measure: Predictors for the course of recovery of COVID-19 infection after hospital admission

Time: 12 months

Description: Healthcare provider and patient satisfaction and experience with the online application. Patients and healthcare providers are asked about their experiences and opinions on homemonitoring.

Measure: Satisfaction of patients and caregivers with the use of a home monitoring system

Time: 12 months
10 Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial

SARS-CoV-2 infection induces a hyperinflammatory syndrome, causing the acute respiratory distress syndrome, massive lung cell destruction and, as a plausible sequelae, pulmonary fibrosis in COVID-19 patients. Current focus has been on the development of novel immunosuppressant therapies, in order to control the cytokine storm in COVID-19 patients. Thus, the effect of steroids, intravenous immunoglobulin, non-steroidal immunosuppressants, selective cytokine blockade, JAK/STAT pathway inbhibition, and mesenchymal precursor cells have been evaluated. Based on the above information, we propose COLLAGEN-POLYVINYLPYRROLIDONE (Distinctive name: FibroquelMR, active substance: Collagen-polyvinylpyrrolidone, pharmaceutical form: intramuscular injectable solution, with sanitary registration No. 201M95 SSA IV and SSA code: 010 000 3999) as a potential drug for the downregulation of the cytokine storm. Polymerized type I collagen reduces the expression of IL-1β, IL-8, TNF-alpha, TGF-β1, IL-17, Cox-1, leukocyte adhesion molecules (ELAM-1, VCAM- 1 and ICAM-1), some other mediators of inflammation and increases the levels of IL-10 and the number of regulatory T cells. In addition, it promotes the mechanisms of inhibition of tissue fibrosis, without adverse effects in rheumatoid arthritis and osteoarthritis.

NCT04517162
Conditions
  1. Covid19
  2. Cytokine Storm
  3. Regulation of Inflammatory Response
  4. Pulmonary Fibrosis
Interventions
  1. Drug: Collagen-Polyvinylpyrrolidone
MeSH:Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: It will be considered as primary outcome if the patients meet the first criterion, or 2 of the remaining 3: No oxygen required to maintain oxygen saturation more than 92%, Decrease in severity category from Table 1 by at least 1 level, or Reduction in the time of symptoms, by at least 30% compared to placebo and baseline, or recovery of at least 30% the number of lymphocytes compared to placebo and baseline.

Measure: Clinical primary Outcome measure

Time: 14 days

Secondary Outcomes

Description: It will be considered as secondary outcome if the patients meet the first criterion, or 2 of the remaining 3: significant decrease in serum IP-10 (at least 30% compared to placebo and baseline), since this chemokine is directly associated with the progression and severity of COVID-19, significant decrease in serum pro-inflammatory cytokines (TNF-a, IL-1β, IL-7, at least 30% compared to placebo and baseline), significant decrease in the percentage of circulating effector T cells (at least 30% compared to placebo and baseline), or significant improvement from computerized axial tomography at re-examination. This improvement is defined as: a decrease of at least 40% in parenchymal attenuation, the appearance of ground glass, nodular opacities, thickening of interlobular septa and / or thickening of bronchial walls.

Measure: Immunological secondary outcome measure

Time: 3 months
11 Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC)

Methodology: This is a controlled, randomized, multicenter open-label Phase Ib clinical exploratory trial in patients with fibrosing interstitial lung disease secondary to SARS-CoV-2 infection. Patients who give informed consent will be screened for enrolment in the study. Patients that meet the eligibility criteria will be enrolled and randomly allocated in the control arm (best standard of care) or the experimental arm (best standard of care plus IN01 vaccination). The patients enrolled in the control arm of the study will receive standard of care. The primary endpoint is safety, measured by the Frequency and severity of AEs graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. Biochemical and blood count alterations will be also monitored. Safety will be defined based on the frequency and severity of adverse events (AEs) throughout the patient's participation in the study comparing between control and experimental arms. Efficacy will be measured as function of the annual rate of decline in the Forced Vital Capacity (FVC) at 1 year after patient inclusion in the study and the blood oxygen saturation levels at days 1, 14 (w2), d 28 (w4), 42 (w6) and 92 (w12); week 24, week 36 and week 52. High-resolution Computed Tomography (CT) scans will be taken at at baseline and weeks, 12, 24, and 52 to evaluate the resolution of the fibrosing interstitial lung disease. A translational substudy will be included. Objectives: Primary Objective ● To evaluate the safety and tolerability of IN01 vaccine in diagnosed ex-COVID-19 patients that develop fibrotic lung syndrome after infection. Secondary Objectives - To evaluate the effect of IN01 vaccine on Oxygen saturation, pulmonary function, quality of life and fibrosing status in ex-COVID-19 patients that developed fibrosing lung disease after infection. - To assess biomarkers and molecular markers related to the IN01 vaccine mechanism of action.

NCT04537130
Conditions
  1. Pulmonary Fibrosis
  2. Covid19
Interventions
  1. Biological: IN01 vaccine
MeSH:Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Frequency and severity of AEs graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria and hematological alterations that are clinical relevant under physician criteria. Data will be presented as number of AEs classified by severity.

Measure: Safety (Frequency/severity of AEs)

Time: Through study completion, average 1 year

Secondary Outcomes

Description: blood oxygen levels will be measured by a pulse oximeter

Measure: Oxygen saturation

Time: baseline and days 1, 14 (w2), 28 (w4), 42 (w6) and 92 (w12); week 24, week 36 and week 52

Description: St George QoL questionnaire: Disease-specific questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.

Measure: Quality of life (QoL)

Time: baseline and weeks 2, 12, 24, 36 and 52

Description: High-resolution CT to follow fibrotic pattern reviewed by a central radiologist

Measure: Fibrotic pulmonary extension (measured as the size of the lesions)

Time: baseline and weeks, 12, 24, and 52
12 "Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis"

Currently, there is no approved treatment for COVID-19 in France, either for the acute phase, nor for the late chronic phase. the investigator suggest that nintedanib has the potential to block the development of lung fibrosis when initiated early enough to inhibit the activation of mesenchymal cells and the progression of virus-induced pulmonary fibrosis. Computerized Tomography (CT) manifestations of fibrosis or fibrous stripes are described in COVID-19 (Ye, Eur Radiol 2020). Pan et al observed fibrous stripes in 17% patients in the early phase of the disease (Pan, Eur Radiol 2020). Ye et al observed bronchiectasis in 2 patients (15.4%) and evidence of pulmonary fibrosis in 3 patients (23.7%) at HRCT performed at 4 weeks (Ye, Eur Radiol 2020). Long term data are still lacking in patients with COVID-19 and the investigators do not know how many patients will have fibrotic sequelae from the acute illness.

NCT04541680
Conditions
  1. SARS-Cov-2 Induced Pulmonary Fibrosis
Interventions
  1. Drug: Nintedanib 150 MG [Ofev]
  2. Other: Placebo
MeSH:Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Change in Forced Vital Capacity over 12 months assessed by Annual Rate of Decline in FVC in Overall Population

Measure: The primary objective is to assess whether nintedanib slows the progression of lung fibrosis in COVID-19 survivors as assessed by the decline in the forced vital capacity (FVC) over 12 months compared to placebo.

Time: at inclusion and 12 months.

Secondary Outcomes

Description: Rate of decline in DLCO estimated by linear regression of DLCO from baseline to 12 months from DLCO measurement at inclusion, 6 and 12 months

Measure: compare the rate of decline of DLCO over 12 months

Time: at inclusion, 6 and 12 months

Description: Absolute change from baseline in the Six-minute walk test (6MWT) at 12 months

Measure: compare exercise capacity at 12 months

Time: at 12 months

Description: HRCT fibrosis score and HRCT fibrosis extension (visual and computer-based assessment) at inclusion and 12 months

Measure: compare high resolution CT (HRCT) lung opacities extension at 12 months

Time: at inclusion and 12 months

Description: Absolute change from baseline in the total score on the St. George's Respiratory Questionnaire questionnaire at 12 months

Measure: compare change in health-related quality of life

Time: at 12 months

Description: Absolute change from baseline in the Dyspnea score (Multidimensional Dyspnea Profile and mMRC score) at 3, 6, 9 and 12 months

Measure: compare the evolution of dyspnea over time

Time: at 3, 6, 9 and 12 months

Description: The absolute change from baseline Hospital Anxiety and Depression score at 3, 6, 9 and 12 months

Measure: compare change in Depression and anxiety over time

Time: at 3, 6, 9 and 12 months

Description: Biomarker assay (KL-6, NT-proBNP, CRP, D-dimers) at inclusion and 12 months

Measure: compare change in lung injury, pulmonary hypertension and inflammation biomarkers

Time: at inclusion and 12 months

Description: Percentage of patients with a tricuspid regurgitation velocity > 2.5, 2.8 and 3.4 m/sec evaluated at baseline and at 12 months.

Measure: pulmonary hypertension prevalence at inclusion and 12 months

Time: at inclusion and 12 months

Description: MUC5B at risk allele detection at inclusion

Measure: association between genetic susceptibility (MUC5B polymorphism) and lung fibrosis in COVID-19 survivors

Time: at inclusion

Description: Incidence of clinical or biological adverse events with nintedanib versus placebo over 12 months

Measure: safety of nintedanib

Time: over 12 months
13 Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis

A randomized controlled trial to study the efficacy of low dose steroid for 14 days in the treatment of post-covid-19 lung infiltrates

NCT04551781
Conditions
  1. Covid19
Interventions
  1. Drug: 20 Mg Prednisone for 14 days
  2. Drug: control
MeSH:Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: resolution of CT chest infiltrates as evaluated by radiologest on a score of no infiltrates, <5%, 5-25%and >25 % infiltrates

Measure: improved

Time: 14 days
14 A Ph 1, Rndmzd, Dbl-Blinded, Pbo-Controlled, 3-Part Study to Eval the Safety, Tolerability, PK, and PD of TD-1058 Admin by Inhalation of Single (A) and Multiple (B) Ascending Doses in Healthy Subjs and Subjs With IPF (C)

This is a Phase 1, 3-part, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1058 inhaled solution. Part A is a SAD study in healthy subjects, Part B is a MAD study in healthy subjects, and Part C is a multiple-dose study in subjects with IPF.

NCT04589260
Conditions
  1. Idiopathic Pulmonary Fibrosis (IPF)
Interventions
  1. Drug: TD-1058
  2. Drug: Placebo
MeSH:Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Number and severity of treatment emergent adverse events

Measure: Part A (SAD) - Adverse Events

Time: Part A (SAD) Day 1 to Day 8

Description: Number and severity of treatment emergent adverse events

Measure: Part B (MAD) - Adverse Events

Time: Part B (MAD) Day 1 to Day 21

Description: Number and severity of treatment emergent adverse events

Measure: Part C (IPF) - Adverse Events

Time: Part C (IPF) Day 1 to Day 35

Secondary Outcomes

Description: Multiple PK variables of TD-0903 will be assessed during Part A, B and C and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)

Measure: Pharmacokinetics (PK) of TD-1058: AUC

Time: Part A (SAD) Day 1 to Day 8 Part B (MAD) Day 1 to Day 21 Part C (IPF) Day 1 to Day 35

Description: Multiple PK variables of TD-0903 will be assessed during Part A, B and C and may include, but are not limited to: Maximum observed concentration (Cmax)

Measure: Pharmacokinetics (PK) of TD-1058: Cmax

Time: Part A (SAD) Day 1 to Day 8 Part B (MAD) Day 1 to Day 21 Part C (IPF) Day 1 to Day 35

Description: Multiple PK variables of TD-0903 will be assessed during Part A, B and C and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)

Measure: Pharmacokinetics (PK) of TD-1058: Tmax

Time: Part A (SAD) Day 1 to Day 8 Part B (MAD) Day 1 to Day 21 Part C (IPF) Day 1 to Day 35
15 Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis

Study population: Patients with fibrotic lung sequelae after recovery from acute phase of severe COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administered for 24 weeks in patients who have pulmonary fibrotic changes after suffering severe COVID19 pneumonia, analysed by - % change in forced vital capacity (FVC) - % fibrosis in high resolution computed tomography (HRCT) of the lung

NCT04607928
Conditions
  1. Fibrotic Pulmonary Sequelae Post-COVID19 Infection
Interventions
  1. Drug: Pirfenidone
  2. Drug: Placebo
MeSH:Pulmonary Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: To investigate the effect of pirfenidone administered for 24 weeks measuring the number of patients who have pulmonary fibrotic changes from baseline after suffering severe COVID19 pneumonia, analysed by Change From Baseline in % in forced vital capacity (FVC) Change From Baseline % fibrosis in high resolution computed tomography (HRCT) of the lung

Measure: To investigate the effect of pirfenidone on fibrotic signs induced by COVID19 infection

Time: 24 weeks

Secondary Outcomes

Description: Number of patients who show maintenance of stability or functional improvement: stability will be considered when the FVC does not increase more than 10% or does not decrease more than 10% and the DLCO does not increase more than 15% or decreases more than 15%. An increase in% FVC greater than 10% or in DLCO greater than 15% will be considered significant improvement.

Measure: Maintenance of stability or functional improvement FVC

Time: 24 weeks

Description: Rate of decreased oxygen requirement for physical activity in patients

Measure: Decreased oxygen requirement for physical activity

Time: 24 weeks

Description: Number of patients who have improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m

Measure: Improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m

Time: 24 weeks

Description: Number of Hospitalizations (general and due to respiratory problems)

Measure: Hospitalizations (general and due to respiratory problems)

Time: 24 weeks

Description: Number of Visits to the Emergency or Day Hospital for respiratory causes

Measure: Visits to the Emergency or Day Hospital for respiratory causes

Time: 24 weeks

Description: Number of patients who need Lung transplantation

Measure: Lung transplantation

Time: 24 weeks

Description: Number of patients who die

Measure: Death

Time: 24 weeks
16 Early Nintedanib Deployment in COVID-19 Interstitial Fibrosis

This is a collaborative study between Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim Pharmaceuticals to determine the effect of Nintedanib on slowing the rate of lung fibrosis in patients who have been diagnosed with COVID-19, and have ongoing lung injury more than 4 weeks out from their diagnosis.

NCT04619680
Conditions
  1. Pulmonary Fibrosis
  2. Interstitial Lung Disease
  3. Respiratory Disease
Interventions
  1. Drug: Nintedanib
  2. Drug: Placebo
MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial Respiration Disorders Respiratory Tract Diseases Fibrosis
HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

Primary Outcomes

Description: Change in Forced Vital Capacity (FVC) at 180 days as compared to baseline. Forced vital capacity (FVC) is the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured by spirometry.

Measure: Change in Forced Vital Capacity (FVC)

Time: Baseline and 180 days

Secondary Outcomes

Description: Death within 90 days and 180 days from enrollment due to a respiratory cause

Measure: Number of deaths due to respiratory cause

Time: within 90-180 days

Description: Quantitative Change in chest CT visual score graded by blinded chest radiologists. Data driven texture analysis (DTA) is a patented deep learning method to quantify lung fibrosis. DTA score is reported in percentage ranging from 0% to 100%. A minimally clinical important difference when comparing CT scans from the same subject is 4%. A higher percentage suggests worsening lung injury.

Measure: Chest CT visual score

Time: 180 days

Description: The Saint George's Respiratory Questionnaire (SGRQ) is a self-reported disease-specific, health-related quality of life (QOL) questionnaire. 50-item instrument. Scores range from 0 to 100, with higher scores indicating more limitations.

Measure: St. George's Respiratory Questionnaire (SGRQ)

Time: Day 90

Description: The Saint George's Respiratory Questionnaire (SGRQ) is a self-reported disease-specific, health-related quality of life (QOL) questionnaire. 50-item instrument. Scores range from 0 to 100, with higher scores indicating more limitations.

Measure: St. George's Respiratory Questionnaire (SGRQ)

Time: Day 180

Description: The King's Brief Interstitial Lung Disease (KBILD) questionnaire is a self-administered, ILD-specific measure of health-related quality of life, comprising 15 items with three domains (Psychological (KBILD-P), Breathlessness and activities (KBILD-B), and Chest symptoms (KBILD-C)) combined in a total score (KBILD-T). The KBILD domain and total score ranges are 0-100; 100 represents best health status.

Measure: King's Brief Interstitial Lung Disease (KBILD)

Time: Day 90

Description: The King's Brief Interstitial Lung Disease (KBILD) questionnaire is a self-administered, ILD-specific measure of health-related quality of life, comprising 15 items with three domains (Psychological (KBILD-P), Breathlessness and activities (KBILD-B), and Chest symptoms (KBILD-C)) combined in a total score (KBILD-T). The KBILD domain and total score ranges are 0-100; 100 represents best health status.

Measure: King's Brief ILD (KBILD)

Time: Day 180

Description: The LCQ is a 19 item questionnaire that assesses cough-related QOL. It has 3 domains (physical, psychological and social). The domain scores range from 1-7 and total score range is 3-21 with a higher score indicating a better quality of life.

Measure: Leicester Cough Questionnaire (LCQ)

Time: Day 90

Description: The LCQ is a 19 item questionnaire that assesses cough-related QOL. It has 3 domains (physical, psychological and social). The domain scores range from 1-7 and total score range is 3-21 with a higher score indicating a better quality of life.

Measure: Leicester Cough Questionnaire

Time: Day 180

Description: The (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status. Scores range from 0 - 100, with higher scores indicating less disability.

Measure: Short Form (SF) 36 Health Survey

Time: Day 90

Description: The (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status. Scores range from 0 - 100, with higher scores indicating less disability.

Measure: SF 36 Health Survey

Time: Day 180

Description: Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression. 14-items scale with responses scored from 0-3, scores for each subscale from 0 (normal) to 21 (severe symptoms). Scores for the entire scale is 0 to 42, with higher score indicating more distress.

Measure: Hospital Anxiety and Depression Scale (HADS)

Time: Day 90

Description: Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression. 14-items scale with responses scored from 0-3, scores for each subscale from 0 (normal) to 21 (severe symptoms). Scores for the entire scale is 0 to 42, with higher score indicating more distress.

Measure: Hospital Anxiety and Depression Scale (HADS)

Time: Day 180

Description: Number of participants with Increase in liver transaminases

Measure: Number of participants with Increase in liver transaminases (AST and ALT) > 3 times the upper limit of normal

Time: day 90

Description: Number of participants with Increase in liver transaminases

Measure: Number of participants with Increase in liver transaminases (AST and ALT) > 3 times the upper limit of normal

Time: day 180

Description: Number of participants with Thrombotic events: venous or arterial thrombosis

Measure: Number of participants with Thrombotic events

Time: day 90

Description: Number of participants with Thrombotic events: venous or arterial thrombosis

Measure: Number of participants with Thrombotic events

Time: day 180

Description: Number of participants with 10% weight loss

Measure: Number of participants with 10% weight loss over 90 days

Time: day 90

Description: Number of participants with 10% weight loss

Measure: Number of participants with 10% weight loss over 90 days

Time: day 180

Description: Number of participants with Nausea/emesis/diarrhea not responsive to anti-emetics and anti-motility agents

Measure: Number of participants with GI events

Time: day 90

Description: Number of participants with Nausea/emesis/diarrhea not responsive to anti-emetics and anti-motility agents

Measure: Number of participants with GI events

Time: day 180
17 Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This Phase 1b trial is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of oral ORIN1001 at 25 mg, 50 mg or 100 mg administered daily for up to 28 days in adult subjects with idiopathic pulmonary fibrosis (IPF) alone or in conjunction with local Standard of Care for IPF (pirfenidone or nintedanib). A maximum of 24 evaluable subjects will be required to complete the study. The study will consist of 3 dose cohorts each enrolling a maximum of 8 subjects randomized either to the active (5 subjects) group or placebo (3 subjects) group. Each subject will receive daily oral doses of ORIN1001 or placebo for 28 days. The safety and pharmacokinetic profile will be evaluated in this study and will include cardiovascular and pulmonary endpoints.

NCT04643769
Conditions
  1. Idiopathic Pulmonary Fibrosis
Interventions
  1. Drug: ORIN1001
  2. Drug: Placebo
MeSH:Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: measurement of blood pressure

Measure: Blood pressure

Time: Up to 60 days

Description: measurement of heart rate

Measure: Heart Rate

Time: Up to 60 days

Description: Measurement of respiratory rate

Measure: Respiratory Rate

Time: Up to 60 days

Description: Measurement of body temperature

Measure: Body Temperature

Time: Up to 60 days

Description: Cardiovascular evaluation to determine intervals including QTc interval

Measure: 12-lead ECG

Time: Up to 60 days

Description: ALT, albumin, ALP, AST, BUN, Ca, Cl, Cholesterol, Creatinine, CK, CA, Elastase, GGT, glucose, HDL, LDH, lipase, LDL, phosphorus, sodium, Total bilirubin, Total protein, Triglycerides, Uric acid, Lipid panel

Measure: Serum Clinical Chemistry analysis

Time: Up to 60 days

Description: WBC, RBC, Hb, HCT, MCV, MCH, MCHC, Neu, Lymphocytes, EOS, Bas, PLT

Measure: Whole blood Hematology analysis

Time: Up to 60 dys

Description: PT, APTT, INR

Measure: Whole blood Coagulation Parameters

Time: Up to 60 days

Description: Bilrubin, glusoe, ketones, leukocytes, nitrite, blood, pH, specific gravity, protein, urobilinogen

Measure: Urinalysis

Time: Up to 60 days

Description: Evaluation of other medications taken currently with investigative drug

Measure: Concomitant medications

Time: Up to 60 days

Description: Medical Health examination, medical history, medicine history, reproductive history, baseline information

Measure: Physical examination

Time: Up to 60 days

Description: Body weight in kg

Measure: Body weight

Time: Up to 60 days

Description: Pulmonary Function Tests: Forced vital capacity (FVC), Forced expiratory volume (FEV)

Measure: Spirometry

Time: Up to 60 days

Description: Height in cm

Measure: Height

Time: Up to 60 days

Description: Calculation of BMI using weight (kg) and height (cm)

Measure: Body mass index (BMI)

Time: Up to 60 days

Description: Lung test to assess diffusion capacity

Measure: DLCO - Assessment of diffusion capacity

Time: Up to 60 days

Secondary Outcomes

Description: Blood collection for evaluation of ORIN1001 exposure. Measurements will assess half life, exposure, maximum concentration, time to maximum concentration and accumulation ratios

Measure: Blood collection to measure drug concentration over time

Time: Up to 29 days

Other Outcomes

Description: Blood collection for evaluation of disease biomarker of lung fibrosis: SP-D, MMP-7 and KL6. Specific biomarker to be determined

Measure: Exploratory biomarkers to evaluate lung fibrosis

Time: Up to 60 days

Description: Questionnaire to assess the quality of life during the study period

Measure: Quality of Life Questionnaire

Time: Up to 60 days

Description: Blood collection for evaluation of inflammation such as cytokines TGF-B and/or IL-6

Measure: Exploratory biomarkers to evaluate inflammation

Time: Up to 60 days
18 Multicenter, Open-label Prospective Cohort Study of the Efficacy and Safety of the Inclusion of Longidaze in the Prevention and Treatment of Post-inflammatory Pulmonary Fibrosis and Interstitial Lung Diseases Caused by COVID-19.

A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.

NCT04645368
Conditions
  1. Fibroses, Pulmonary
Interventions
  1. Drug: bovhyaluronidase azoxymer
MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial Fibrosis
HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

Primary Outcomes

Description: The severity of pulmonary tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group according to the results of a blinded central laboratory

Measure: The severity of lung tissue lesions with fibrosis and interstitial changes on day 75

Time: Day 0, Day 75

Secondary Outcomes

Description: The severity of lung tissue damage by fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 6 months in relation to the baseline values of the indicator in patients of the Longidaze® group in comparison with the the dynamic observation group (according to the results of a blinded central laboratory)

Measure: The severity of lung tissue damage by fibrosis and interstitial changes (%) on day 180

Time: Day 0, Day 180

Description: The severity of lung tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group (according to the results of the local laboratory)

Measure: The severity of lung tissue lesions with fibrosis and interstitial changes (%) on day 75 and day 180

Time: Day 0, Day 75, Day 180

Description: The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) based on the high-resolution computed tomography images analyzed by the Botkin.AI program (artificial intelligence) and then verified by a specialist after 2.5 months and 6 months from the beginning of observation in relation to the baseline values of indicators in patients of the Longidaze® group in comparison with the dynamic observation group

Measure: The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) images analyzed by the Botkin.AI program (artificial intelligence)

Time: Day 75, Day 180

Description: Change in forced vital capacity FVC (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group

Measure: Change in forced vital capacity (FVC)

Time: Day 0, Day 75, Day 180

Description: Change in the diffusion capacity of the lungs (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group

Measure: Change in the diffusion capacity of the lungs

Time: Day 0, Day 75, Day 180

Description: Change in the degree of dyspnea on the MMRC scale from baseline after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group. MMRC scale (Modified Medical Research Council scale) 0 - no - Dyspnea does not bother, except for very intense exercise - mild - Shortness of breath bothers with brisk walking or climbing a small elevation - moderate to severe - Shortness of breath results in slower walking compared to other people of the same age, or need to stop while walking at normal pace on a level surface - Severe - Shortness of breath makes you stop when walking about 100 m or after a few minutes of walking on a flat surface - very severe - Shortness of breath makes it impossible to leave the house or appears when dressing and undressing

Measure: Change in the degree of dyspnea on the MMRC scale

Time: Day 0, Day 75, Day 180

Description: Changes in SpO2 of capillary blood relative to the initial value after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

Measure: Changes in capillary blood oxygen saturation (SpO2)

Time: Day 0, Day 75, Day 180

Description: Changes in the covered footage in the 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

Measure: Changes in the covered footage in the 6-minute walk test

Time: Day 0, Day 75, Day 180

Description: Changes in capillary blood saturation (SpO2) after a 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

Measure: Changes in capillary blood saturation (SpO2) after a 6-minute walk test

Time: Day 0, Day 75, Day 180

Description: Change in the residual volume of the lungs after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group.

Measure: Change in the residual volume of the lungs

Time: Day 0, Day 75

Description: Change in the total lung capacity after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group.

Measure: Change in the total lung capacity

Time: Day 0, Day 75

Description: Change in inspiratory capacity after 2.5 months in patients of the Longidaze® group compared with dynamic observation group

Measure: Change in inspiratory capacity

Time: Day 75

HPO Nodes


Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook